Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.36, ...

The work is published in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common ...

26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). “This positive CHMP opinion is a welcome advancement for physicians and patients in Europe ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

I found purpose after my AML diagnosis by reflecting on loss, embracing gratitude and using my experience to help others ...

The treatment of leukemia among children could be made more precise with fewer side effects with the help of more accurate ...

Outcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease Concurrently performed, our trial's primary ...

Acute lymphocytic leukaemia (ALL) is a cancer of the blood and bone marrow, specifically affecting lymphocytes. The disease progresses rapidly and creates immature blood cells, rather than mature ...

Autolus Therapeutics (AUTL) stock in focus as the company wins EU panel's endorsement for leukemia therapy. Read more here.

I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace ...

Abby, who was diagnosed with B-cell acute lymphoblastic leukemia, has to fight off even the smallest infection.